BACKGROUND: Pakistan introduced Ten-valent pneumococcal-conjugate-vaccine PCV10 in 2012 as a 3 + 0 schedule without catch-up. METHODS: Children <2 years old in Matiari, Sindh provided nasopharyngeal swabs between 2014 and 2018, which were cultured for pneumococcus and serotyped through multiplex PCR at the Aga Khan University Hospital. Carriage rates over time for Vaccine-Type (VT) and Non-VT (NVT) serotypes were used to estimate direct, indirect, total and overall effects of vaccination. Regression analysis was used to determine factors associated with VT carriage. RESULTS: Pneumococcus was detected in 2370/3140 (75%). VT carriage decreased overall, 16.1-9.6% (p-trend <0.001); vaccinated (all 3 doses of PCV10 received) 11.3-8.1% (p-trend 0.031) and unvaccinated (no PCV10 dose received) 17.4-10.3% (p-trend 0.003) with a decline in serotypes 6B, 9V/9A and 19F. Immunization increased from 41.0% to 68.4% (p-trend 0.001). Direct effect of vaccine was 32.8% (95% CI 14.7-47.0%) and indirect effect 44.6%(95% CI 40.6-48.6%). Factors associated with decreased VT colonization were education 1-5 years (aOR 0.7, 95%CI 0.6-1.0), history of difficulty breathing (aOR 0.7, 95%CI 0.5-1.0), exposure to smoke (aOR 0.8, 95% CI 0.6-1.0), child fully immunized (aOR 0.7, 95%CI 0.5-1.0) and enrolled in 3rd (aOR 0.6, 95%CI 0.4-0.8) and 4th (aOR 0.6, 95%CI 0.5-0.9) year of the study whereas history of runny nose (aOR 1.5, 95% CI 1.2-1.9) was positively associated. CONCLUSIONS: Decrease in VT pneumococcal carriage in vaccinated and unvaccinated children indicates herd immunity. Sustained increase in vaccine coverage and close long-term surveillance is warranted.
BACKGROUND: Pakistan introduced Ten-valent pneumococcal-conjugate-vaccine PCV10 in 2012 as a 3 + 0 schedule without catch-up. METHODS:Children <2 years old in Matiari, Sindh provided nasopharyngeal swabs between 2014 and 2018, which were cultured for pneumococcus and serotyped through multiplex PCR at the Aga Khan University Hospital. Carriage rates over time for Vaccine-Type (VT) and Non-VT (NVT) serotypes were used to estimate direct, indirect, total and overall effects of vaccination. Regression analysis was used to determine factors associated with VT carriage. RESULTS: Pneumococcus was detected in 2370/3140 (75%). VT carriage decreased overall, 16.1-9.6% (p-trend <0.001); vaccinated (all 3 doses of PCV10 received) 11.3-8.1% (p-trend 0.031) and unvaccinated (no PCV10 dose received) 17.4-10.3% (p-trend 0.003) with a decline in serotypes 6B, 9V/9A and 19F. Immunization increased from 41.0% to 68.4% (p-trend 0.001). Direct effect of vaccine was 32.8% (95% CI 14.7-47.0%) and indirect effect 44.6%(95% CI 40.6-48.6%). Factors associated with decreased VT colonization were education 1-5 years (aOR 0.7, 95%CI 0.6-1.0), history of difficulty breathing (aOR 0.7, 95%CI 0.5-1.0), exposure to smoke (aOR 0.8, 95% CI 0.6-1.0), child fully immunized (aOR 0.7, 95%CI 0.5-1.0) and enrolled in 3rd (aOR 0.6, 95%CI 0.4-0.8) and 4th (aOR 0.6, 95%CI 0.5-0.9) year of the study whereas history of runny nose (aOR 1.5, 95% CI 1.2-1.9) was positively associated. CONCLUSIONS: Decrease in VT pneumococcal carriage in vaccinated and unvaccinated children indicates herd immunity. Sustained increase in vaccine coverage and close long-term surveillance is warranted.
Authors: Betuel Sigaúque; Benild Moiane; Sergio Massora; Fabiana Pimenta; Jennifer R Verani; Helio Mucavele; Alberto Chaúque; Llorenç Quintó; Rita T Dos Santos; Maria da Gloria Carvalho; Cynthia G Whitney; Fernanda C Lessa Journal: Pediatr Infect Dis J Date: 2018-10 Impact factor: 2.129
Authors: Maria da Gloria Carvalho; Fabiana C Pimenta; Delois Jackson; Alexis Roundtree; Yusra Ahmad; Eugene V Millar; Katherine L O'Brien; Cynthia G Whitney; Adam L Cohen; Bernard W Beall Journal: J Clin Microbiol Date: 2010-03-10 Impact factor: 5.948
Authors: Anita M Loughlin; Katherine Hsu; Amy L Silverio; Colin D Marchant; Stephen I Pelton Journal: Pediatr Infect Dis J Date: 2014-05 Impact factor: 2.129
Authors: Claire von Mollendorf; Eileen M Dunne; Sophie La Vincente; Mukhchuluun Ulziibayar; Bujinlkham Suuri; Dashtseren Luvsantseren; Dorj Narangerel; Belinda D Ortika; Casey L Pell; Monica L Nation; Ahmed Alamrousi; Jason Hinds; Sodbayar Demberelsuren; Cattram Nguyen; Tuya Mungun; E Kim Mulholland; Catherine Satzke Journal: Vaccine Date: 2019-06-04 Impact factor: 3.641
Authors: Katherine L O'Brien; Lara J Wolfson; James P Watt; Emily Henkle; Maria Deloria-Knoll; Natalie McCall; Ellen Lee; Kim Mulholland; Orin S Levine; Thomas Cherian Journal: Lancet Date: 2009-09-12 Impact factor: 79.321
Authors: Laura L Hammitt; Anthony O Etyang; Susan C Morpeth; John Ojal; Alex Mutuku; Neema Mturi; Jennifer C Moisi; Ifedayo M Adetifa; Angela Karani; Donald O Akech; Mark Otiende; Tahreni Bwanaali; Jackline Wafula; Christine Mataza; Edward Mumbo; Collins Tabu; Maria Deloria Knoll; Evasius Bauni; Kevin Marsh; Thomas N Williams; Tatu Kamau; Shahnaaz K Sharif; Orin S Levine; J Anthony G Scott Journal: Lancet Date: 2019-04-15 Impact factor: 79.321
Authors: Ellen Heinsbroek; Terence Tafatatha; Amos Phiri; Todd D Swarthout; Maaike Alaerts; Amelia C Crampin; Christina Chisambo; Oddie Mwiba; Jonathan M Read; Neil French Journal: Vaccine Date: 2018-10-21 Impact factor: 3.641
Authors: Eleanor F G Neal; Cattram D Nguyen; Felista T Ratu; Eileen M Dunne; Mike Kama; Belinda D Ortika; Laura K Boelsen; Joseph Kado; Lisi Tikoduadua; Rachel Devi; Evelyn Tuivaga; Rita C Reyburn; Catherine Satzke; Eric Rafai; E Kim Mulholland; Fiona M Russell Journal: PLoS One Date: 2020-04-01 Impact factor: 3.240